Automation for autologous cell therapies moved closer to scalability as Cellares’ Cell Shuttle platform produced GMP material for rese-cel, with the first two patients dosed following release criteria verification. The announcement underscores the field’s focus on lowering manufacturing cost of goods and eliminating manual variability. The rese-cel program is engineered for autoimmune indications using a single infusion designed to transiently and deeply deplete CD19-positive cells to “reset” immune function. In parallel, the company positioned this dosing as a milestone demonstrating supply-chain capabilities with minimal capital investment. For investors and partners, the operational signal is that automated, standardized manufacturing platforms can meet regulatory release expectations early in clinical programs—reducing one of the biggest barriers to broader access.